"name","text","uuid:ID","instanceType","description","label","id"
"OBJ1","To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).","4da2a236-b655-4bb7-886d-5b4ea186db2b","Objective","Main objective","","Objective_1"
"OBJ2","To document the safety profile of the xanomeline TTS.","b2ccbbbe-0f23-41a3-b069-888249f592ca","Objective","Safety","","Objective_2"
"OBJ3","To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.","69fb6c25-ce97-4032-ab77-ade1378255c4","Objective","Behaviour","","Objective_3"
"OBJ4","To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas (see Attachment LZZT.5).","28933093-e585-49c0-a31c-9016545a705e","Objective","","","Objective_4"
"OBJ5","To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer's Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment (see Attachment LZZT.2).","4b921279-b5fd-4aee-9b91-2df330671c8a","Objective","","","Objective_5"
"OBJ6","To assess the treatment response as a function of Apo E genotype.","775c7516-baa4-470f-94d8-1aea267edf6a","Objective","","","Objective_6"
